MarketPeel
Insider Trading Intelligence
Pricing
…
SG

Steven Gillis

PULM
DIRECTOR · PULMATRIX, INC. · CIK 0001229592
FILING MIX · LIFETIME61%/39%
BUYS
55
SELLS
35
TOTAL VALUE
$114.93M
COMPANIES
9
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
43,827,425
AVG SELL PX
—
TRADE KIND
SHOWING 90 / 90
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
18 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Steven Gillis, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d18+55.56%+0.88%+1.26%-0.39%+0.31%—
14d18+55.56%-3.85%+2.50%-6.34%-2.57%—
30d18+55.56%+3.26%+2.14%+1.13%+2.52%—
60d18+72.22%+18.85%+7.30%+11.55%+20.74%—
90d18+88.89%+34.52%+12.35%+25.58%+36.04%—
180d18(1 pending)+11.76%-13.62%+18.66%-32.28%-33.89%—
1y18(2 pending)+56.25%+2.72%+35.53%-32.80%-28.65%—
2y18(2 pending)+0.00%-78.23%+56.27%-134.49%-134.34%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PULM · 1,771 shares · as of Aug 28, 2020
03,7507,50011,25015,000SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 55 buys / 35 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KARD
KARDIGAN, INC.
PURCHASE
1,250,000$16.00$20.00M15,042,035Jun 22, 2026Jun 24, 2026 ↗View →
KARD
KARDIGAN, INC.
SALE
2,306,401——0Jun 17, 2026Jun 22, 2026 ↗View →
KARD
KARDIGAN, INC.
PURCHASE
13,792,035——13,792,035Jun 17, 2026Jun 22, 2026 ↗View →
KARD
KARDIGAN, INC.
SALE
5,148,587——0Jun 17, 2026Jun 22, 2026 ↗View →
KARD
KARDIGAN, INC.
SALE
1,204,000——0Jun 17, 2026Jun 22, 2026 ↗View →
LYEL
LYELL IMMUNOPHARMA, INC.
PURCHASE
488,090$25.61$12.50M1,426,528Mar 6, 2026Mar 9, 2026 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,915,700$2.61$5.00M6,046,907Oct 27, 2025Oct 29, 2025 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
3,030,300$3.30$10.00M6,230,300Aug 1, 2025Aug 1, 2025 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE
11,924,138——0Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
SALE
20,000,000——0Jun 10, 2024Jun 10, 2024 ↗View →
RAPP
RAPPORT THERAPEUTICS, INC.
PURCHASE
3,728,738——3,728,738Jun 10, 2024Jun 10, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
SALE
586,080——0Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
SALE
424,908——0Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
PURCHASE
589,743——617,092Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
SALE
164,835——0Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
PURCHASE
787,545——828,570Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
SALE
454,212——0Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
PURCHASE
133,333$16.00$2.13M1,181,766Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
SALE
227,920——0Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
PURCHASE
1,048,433——1,048,433Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
SALE
366,301——0Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
SALE
201,465——0Apr 2, 2024Apr 4, 2024 ↗View →
BOLD
BOUNDLESS BIO, INC.
PURCHASE
66,667$16.00$1.07M683,759Apr 2, 2024Apr 4, 2024 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
3,200,000$6.25$20.00M3,200,000Feb 15, 2024Feb 20, 2024 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
727,272$5.50$4.00M12,446,022Feb 8, 2024Feb 12, 2024 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
363,637$5.50$2.00M10,667,387Feb 8, 2024Feb 12, 2024 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
703,061——1,387,228Dec 8, 2023Dec 12, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,176,593——2,321,566Dec 8, 2023Dec 12, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
3,357$11.98$40.2K4,131,207Nov 14, 2023Nov 15, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
31,653$11.75$371.9K4,127,850Nov 13, 2023Nov 15, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
5,431$11.75$63.8K4,096,197Nov 10, 2023Nov 13, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
11,844$11.37$134.7K4,090,766Nov 10, 2023Nov 13, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
31,079$10.53$327.3K4,078,922Nov 9, 2023Nov 13, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
23,124$11.79$272.6K4,047,843Nov 8, 2023Nov 13, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
69,127$10.78$745.2K4,024,719Nov 8, 2023Nov 13, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
30,192$11.50$347.2K3,955,592Nov 7, 2023Nov 7, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
43,082$11.55$497.6K3,925,400Nov 6, 2023Nov 7, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
22,420$11.38$255.1K3,882,318Nov 3, 2023Nov 7, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
34,560$13.98$483.1K3,859,898Sep 29, 2023Sep 29, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
16,841$13.06$219.9K3,800,228Sep 28, 2023Sep 29, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
25,110$13.69$343.8K3,825,338Sep 28, 2023Sep 29, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
24,504$12.31$301.6K3,783,387Sep 27, 2023Sep 27, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
34,000$11.73$398.8K3,758,883Sep 26, 2023Sep 27, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
30,773$10.80$332.3K3,694,916Sep 25, 2023Sep 25, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
29,967$11.65$349.1K3,724,883Sep 25, 2023Sep 25, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
40,000$11.14$445.6K3,664,143Sep 22, 2023Sep 25, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,144,973——1,144,973Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
6,576,400——11,886,758Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
2,124,143——2,124,143Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
1,500,000$17.00$25.50M3,624,143Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
6,576,400——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
684,167——684,167Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
2,124,143——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
PURCHASE
6,895,021——12,205,379Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
1,144,973——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
684,167——0Sep 19, 2023Sep 19, 2023 ↗View →
NMRA
NEUMORA THERAPEUTICS, INC.
SALE
6,895,021——0Sep 19, 2023Sep 19, 2023 ↗View →
PRME
PRIME MEDICINE, INC.
SALE
1,141,474——0Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
SALE
16,666,667——0Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
SALE
16,666,664——0Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
5,728,297——5,728,297Oct 24, 2022Oct 26, 2022 ↗View →
PRME
PRIME MEDICINE, INC.
PURCHASE
400,000$17.00$6.80M6,128,297Oct 24, 2022Oct 26, 2022 ↗View →
ERAS
ERASCA, INC.
SALE
3,400,000——0Jul 20, 2021Jul 20, 2021 ↗View →
ERAS
ERASCA, INC.
PURCHASE
5,527,777——5,527,777Jul 20, 2021Jul 20, 2021 ↗View →
ERAS
ERASCA, INC.
SALE
2,100,000——0Jul 20, 2021Jul 20, 2021 ↗View →
ERAS
ERASCA, INC.
SALE
1,133,333——0Jul 20, 2021Jul 20, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
10,156,250——10,303,750Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
5,687,500——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
3,687,500——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
781,250——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
2,343,750——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
10,156,250——10,301,250Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
SALE
9,375,000——0Feb 8, 2021Feb 10, 2021 ↗View →
SANA
SANA BIOTECHNOLOGY, INC.
PURCHASE
11,718,750——11,718,750Feb 8, 2021Feb 10, 2021 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
880——880Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
SALE
10,000——0Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
SALE
440——0Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
SALE
1,771——0Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
SALE
15,000——0Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
111——111Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
SALE
111——0Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
440——440Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
12,400——12,400Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
SALE
880——0Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
10,000——10,000Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
SALE
12,400——0Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
1,771——1,771Aug 28, 2020Sep 1, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
10,000——10,000Apr 2, 2020Apr 6, 2020 ↗View →
PULM
PULMATRIX, INC.
PURCHASEGRANT
Stock grant
15,000——15,000Jan 9, 2020Jan 13, 2020 ↗View →
Other insiders · PULM
Loading peer insiders…
About this filer
CIK 0001229592
ROLE
Director
PRIMARY
PULM
COMPANIES
9
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001229592DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback